Table 1.
Clinicopathological characteristics.
| N=353 | |
|---|---|
|
| |
| Median (min–max) | |
| Age (years) | 48 (24–79) |
|
| |
| Tumor size (cm) | 2.2 (0.3–14) |
|
| |
| Total excised lymph nodes | 14 (1–43) |
|
| |
| Total involved lymph nodes | 1 (0–42) |
|
| |
| Adjuvant chemotherapy cures | 6 (4–8) |
|
| |
| Radiotherapy dose (Gray) | 50 (45–54.4) |
|
| |
| N (%) | |
|
| |
| Menopausal status | |
| Premenopausal | 177 (50.1) |
| Postmenopausal | 165 (46.7) |
| Perimenopausal | 11 (3.1) |
|
| |
| Pathology | |
| IDC + ILC | 52 (14.7) |
| IDC | 255 (72.2) |
| ILC | 30 (8.5) |
| Other | 16 (5.6) |
|
| |
| Surgery type | |
| BCS+SLNB | 86 (24.4) |
| MRM | 135 (38.3) |
| Mastectomy+SLNB | 9 (2.5) |
| BCS+AD | 113 (32) |
| SSM+AD | 7 (2) |
| NSM+AD | 2 (0.6) |
| SSM+SLNB | 1 (0.3) |
|
| |
| Tumor grade | |
| 1 | 19 (5.4) |
| 2 | 154 (43.6) |
| 3 | 180 (51) |
|
| |
| ER | |
| Positive | 253 (71.7) |
| Negative | 100 (28.3) |
|
| |
| PR | |
| Positive | 265 (75.1) |
| Negative | 88 (24.9) |
|
| |
| HER2 | |
| Positive | 64 (18.1) |
| Negative | 289 (81.9) |
|
| |
| Triple negative | |
| Yes | 41 (11.6) |
| No | 312 (88.4) |
|
| |
| Adjuvant chemotherapy | |
| Yes | 282 (79.9) |
| No | 71 (20.1) |
|
| |
| HT | |
| Yes | 288 (81.6) |
| No | 65 (18.4) |
|
| |
| Radiotherapy | |
| Yes | 315 (89.2) |
| No | 38 (10.8) |
|
| |
| Loco-regional | |
| Yes | 23 (6.5) |
| No | 330 (93.5) |
|
| |
| Distant metastasis | |
| Yes | 71 (20.1) |
| No | 282 (79.9) |
|
| |
| Status | |
| Exitus (due to breast cancer) | 56 (15.9) |
| Alive | 232 (65.7) |
| Lost to follow-up | 50 (14.2) |
| Exitus (other reasons) | 15 (4.2) |
IDC – invasive ductal carcinoma; ILC – invasive lobular carcinoma; BCS – breast conserving surgery; SLNB – sentinel lymph node biopsy; MRM – modified radical mastectomy; AD – axillary dissection; SSM – skin sparing mastectomy; NSM – nipple sparing mastectomy; ER – estrogen receptor; PR – progesterone receptor.